DEVELOPMENT AND SUPPLY AGREEMENTDevelopment and Supply Agreement • May 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances) • New York
THIS DEVELOPMENT AND SUPPLY AGREEMENT (this "Agreement") is made as of this 25th day of March, 2009 (the "Effective Date") by and between NPS Pharmaceuticals, Inc., having a principal place of business at 550 Hills Drive, 3rd Floor, Bedminster, NJ 07921 ("Company") and Hospira Worldwide, Inc., having a principal place of business at 275 North Field Drive, Lake Forest, Illinois, 60045, (U.S.A.) ("Hospira").
Mr. Joseph Rogus Vice President Technical Operations NPS Pharmaceuticals 550 Hills Drive 3rd Floor Bedminster, NJ 07921 Letter Agreement BOC Biopharmaceuticals / Operations 19 January 2009 Dr. Monika Henninger Phone ++43-1-80 105-2141 Telefax...NPS Pharmaceuticals Inc • May 3rd, 2011 • Biological products, (no disgnostic substances)
Dear Mr. Rogus, As you know, Boehringer Ingelheim RCV GmbH & Co KG ("BI RCV"), which is the universal legal successor into all rights and obligations of Boehringer Ingelheim Austria GmbH, on the one hand, and NPS Pharmaceuticals, Inc. ("NPS", and BI RCV together with NPS, the "Parties"), which has assumed all rights and obligations of NPS Allelix Corp. vis-à-vis Boehringer Ingelheim Austria GmbH and BI RCV, respectively, on the other hand, are the Parties to a certain Commercial Manufacturing Agreement of 18 October 2002 for the manufacture of product PTH[1-84] ("rhPTH") ("Commercial Manufacturing Agreement"). The Commercial Manufacturing Agreement has subsequently been amended by the Amending Agreement of 15 March 2004, which, inter alia, also governs services for and the manufacture of product ALX-0600. The Commercial Manufacturing Agreement and the Amending Agreement have subsequently been amended by Amendment Number One to Amending Agreement, effective as of 22 December 2005 ("Amen
AMENDMENT NUMBER TWO TO AMENDING AGREEMENTAmending Agreement • May 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
WHEREAS, the Parties have entered into a COMMERCIAL MANUFACTURING AGREEMENT dated as of OCTOBER 18, 2002 (hereinafter, the "AGREEMENT") for the manufacture of NPS ALLELIX proprietary product ALX-11 (also known as PREOS®), for which the active ingredient is recombinant human parathyroid hormone eighty-four (84) amino acids ("rhPTH"); and
AMENDMENT NUMBER THREE TO AMENDING AGREEMENTAmending Agreement • May 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)
THIS AMENDMENT Number Three ("Amendment Number Three"), effective as of the 1st day of February, 2011 ("Amendment No Three Effective Date"), is entered into
